Q1 2025 Dare Bioscience Inc Earnings Call Transcript

May 13, 2025 / 08:30 PM GMT

Release Date Price: $2.89 (+0.35%)

Transcript 10-Q8-K

Key Points

Positve

Dare Bioscience Inc (DARE) is expanding its product offerings with three new solutions for women, including two vaginal probiotics in 2025 and a proprietary monthly hormone therapy in 2026.
The company is leveraging a dual path strategy to commercialize its products via 503b compounding while continuing to seek FDA approval, accelerating market availability.
Dare Bioscience Inc (DARE) is targeting the $4.5 billion compounded hormone therapy market, creating significant commercial opportunities.
The company has reduced its general and administrative expenses by 14% and R&D expenses by 31% compared to Q1 2024, indicating effective cost management.
Dare Bioscience Inc (DARE) is actively pursuing strategic partnerships and collaborations to enhance product accessibility across multiple channels.

Negative

The company reported a comprehensive loss of approximately $4.4 million for the first quarter of 2025.
Dare Bioscience Inc (DARE) has a working capital deficit of approximately $9.4 million, which may impact its financial flexibility.
The company is still in the process of securing manufacturing capacity for its products, which may delay market entry.
There is uncertainty regarding the enrollment rate for the pivotal phase 3 contraceptive efficacy study of Ovaprine.
The company's dual path strategy may face challenges in balancing regulatory requirements and market demands.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

DARE.OQ - Dare Bioscience Inc
Q1 2025 Dare Bioscience Inc Earnings Call
May 13, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the conference call hosted by Dara Bioscience to review the company's first quarter, 2025 financial results and to provide a business update. This call is being recorded. My name is Gail and I will be your operator today. With us today from Dara are Sabrina Martucci Johnson, President and Chief Executive Officer, and Marty Harding Leyton, Chicounting Officer. Ms. Harding Leyton, please proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon and welcome to the Dari Bioscience Financial Results and Business update call for the quarter ended March 30, 2025.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.